+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
PPARd Agonist Market by Therapeutic Application, Pharmaceutical Formulations, Mechanism of Action, Development Stages, Distribution Channels, Target Demographics, Research and Development Platforms, Combination Therapies - Global Forecast to 2030- Product Image
PPARd Agonist Market by Therapeutic Application, Pharmaceutical Formulations, Mechanism of Action, Development Stages, Distribution Channels, Target Demographics, Research and Development Platforms, Combination Therapies - Global Forecast to 2030- Product Image
Sale

PPARd Agonist Market by Therapeutic Application, Pharmaceutical Formulations, Mechanism of Action, Development Stages, Distribution Channels, Target Demographics, Research and Development Platforms, Combination Therapies - Global Forecast to 2030

  • PDF Icon

    Report

  • 185 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6161040
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Peroxisome proliferator-activated receptor delta (PPARδ) agonists represent a dynamic class of nuclear receptor modulators that have attracted considerable attention for their capacity to regulate lipid metabolism, inflammatory pathways, and cellular energy homeostasis. Emerging research has underscored their potential to address a spectrum of conditions ranging from dyslipidemia and obesity to inflammatory bowel disease and cardiovascular complications. Recent breakthroughs in molecular design have enhanced receptor selectivity and bioavailability, paving the way for precision therapies that minimize off-target effects. As the scientific community continues to unravel the mechanistic underpinnings of PPARδ signaling, pharmaceutical developers are increasingly focused on optimizing formulation strategies and combination regimens to improve patient outcomes. This executive summary distills the most pertinent developments shaping the PPARδ agonist landscape, highlights the evolving regulatory and competitive contexts, and outlines essential insights for stakeholders aiming to capitalize on the therapeutic promise of these agents. By examining transformative shifts, tariff implications, segmentation dynamics, regional nuances, leading industry players, and actionable recommendations, this report equips decision-makers with a comprehensive foundation to steer innovation and market success.

Transformative Shifts in the PPARδ Agonist Landscape

The PPARδ agonist arena has experienced several transformative shifts over the past two years, each of which has redefined research priorities and commercial trajectories. Advances in structural biology have refined ligand-receptor interaction models, enabling the design of allosteric modulators that confer enhanced safety profiles compared to traditional full and partial agonists. In parallel, regulatory authorities have signaled openness to novel endpoints in metabolic and inflammatory disease trials, encouraging sponsors to pursue adaptive study designs and real-world evidence strategies. Moreover, the rise of dual and multi-therapy approaches has unlocked synergistic combinations, particularly in cardiovascular and metabolic indications, where complementarity between PPARδ agonists and established lipid-lowering or anti-inflammatory agents yields superior efficacy. Digital health solutions, including remote monitoring and AI-driven dosing algorithms, have further enriched patient engagement and adherence, while contract research organizations are leveraging decentralized trial platforms to accelerate enrollment across diverse demographics. Collectively, these factors have fostered a more agile, patient-centric ecosystem, positioning PPARδ agonists to transition from experimental compounds to integral components of next-generation therapeutic portfolios.

Cumulative Impact of United States Tariffs 2025 on PPARδ Agonist Development

In 2025, the United States implemented a revised tariff structure affecting key imports integral to PPARδ agonist research and manufacturing, including active pharmaceutical ingredients, high-purity reagents, and specialized fermentation equipment. These elevated duties have exerted upward pressure on input costs, compelling sponsors and contract manufacturers to reassess sourcing strategies and renegotiate supplier agreements. As a result, some companies have accelerated plans to nearshore production or diversify procurement into tariff-exempt jurisdictions, thereby mitigating exposure to volatile trade policies. The tariff adjustments have also prompted a reassessment of pricing strategies in highly competitive indications, particularly metabolic and inflammatory disorders where margin compression is already a concern. Consequently, organizations that integrate robust supply chain analytics and invest in vertical integration stand to preserve cost efficiencies and safeguard research timelines. Moreover, the tariff environment has underscored the strategic value of public-private partnerships, enabling stakeholders to leverage government incentives for domestic manufacturing capacity expansion and foster resilient ecosystems. Ultimately, the 2025 tariff landscape has served as a catalyst for enhanced supply chain agility and cost discipline across the PPARδ agonist value chain.

Key Segmentation Insights for PPARδ Agonists

A nuanced segmentation framework reveals the breadth of opportunity within the PPARδ agonist domain. Based on therapeutic application, research spans cardiovascular disorders-with subfocus on atherosclerosis and peripheral vascular diseases-through inflammatory disorders such as arthritis and inflammatory bowel disease, alongside metabolic conditions including dyslipidemia, obesity and type 2 diabetes, as well as explorations into neurological disorders and oncology. Pharmaceutical formulation strategies extend across inhalable, injectable, oral, topical and transdermal options, each tailored to optimize delivery kinetics and patient adherence. Distinct mechanism-of-action classes encompass allosteric modulators, full agonists, partial agonists and selective agonists, providing a toolkit to balance potency and safety. Development stages range from preclinical discovery and post-marketing studies to approved and marketed products, with clinical trials segmented into phases I, II and III to align with evolving regulatory data requirements. Distribution channels include hospital medication outlets, online platforms, retail pharmacies and wholesalers, facilitating broad market access. Target demographics are defined by age cohorts, gender-specific considerations, lifestyle segments and risk profiles distinguishing high risk and low risk populations. Research and development platforms are diversified across academic institutes-spanning applied and basic research-biotechnology firms and contract research organizations, while combination therapy paradigms comprise monotherapy, dual therapy with synergistic combinations and multi therapy to maximize therapeutic synergy.

Key Regional Insights Shaping the PPARδ Agonist Market

Regional dynamics exert a profound influence on PPARδ agonist development and commercialization. In the Americas, robust regulatory frameworks and well-established reimbursement pathways underpin a thriving innovation ecosystem, with the United States driving most clinical pipeline activity and Canada expanding early-stage collaborations. Europe, Middle East & Africa presents a more fragmented landscape: Europe benefits from harmonized regulatory guidelines and strong public research funding, whereas the Middle East is emerging as an attractive site for clinical trials, and the Africa region requires tailored strategies to address infrastructure and access constraints. Asia-Pacific offers unparalleled growth potential fueled by proactive government initiatives, expanding patient populations and rapidly scaling manufacturing capabilities in countries such as China, India and Japan. Strategic alliances between local biotechnology firms and global pharma players enable accelerated market entry, while regulatory authorities in several Asia-Pacific jurisdictions are adopting expedited review pathways for innovative therapies. Overall, regional insights illuminate critical pathways for targeted investment, regulatory alignment and market access planning.

Leading Companies Driving PPARδ Agonist Innovation

Leading biopharmaceutical companies are actively shaping the trajectory of PPARδ agonist innovation. Industry incumbents such as AbbVie Inc., Alnylam Pharmaceuticals, Amgen Inc. and Astellas Pharma are advancing diversified pipelines with an emphasis on metabolic and inflammatory indications. AstraZeneca PLC, Bayer AG and Boehringer Ingelheim GmbH are leveraging their global development platforms to fast-track clinical candidates into later-stage trials. Collaborative ventures between Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited and Eli Lilly and Company underscore the value of co-development models. Gilead Sciences, GlaxoSmithKline plc and Ipsen S.A. are exploring novel formulation paradigms to enhance bioavailability and patient adherence. Ironwood Pharmaceuticals, Johnson & Johnson and Merck & Co. are integrating digital health solutions into trial designs. Mitsubishi Tanabe Pharma Corporation, Novartis AG, Novo Nordisk A/S and Otsuka Holdings Co. are prioritizing combination therapy research. Pfizer Inc., Regeneron Pharmaceuticals, Roche Holding AG and Sanofi S.A. continue to drive late-stage clinical programs. Sumitomo Dainippon Pharma Co., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Limited and UCB S.A. are exploring partnerships to bolster global reach, while Vertex Pharmaceuticals is pioneering precision medicine approaches to patient stratification. This constellation of players cultivates a competitive yet collaborative environment that accelerates scientific breakthroughs.

Actionable Recommendations for Industry Leaders

Industry leaders should adopt a multifaceted strategy to maximize the potential of PPARδ agonists. First, invest in precision medicine initiatives that leverage genomic and metabolic biomarkers to identify patient subpopulations most likely to benefit from targeted therapies. Second, diversify supply chains by pursuing dual sourcing agreements and nearshoring partnerships that mitigate exposure to tariff fluctuations and logistical disruptions. Third, accelerate clinical development through adaptive trial designs and decentralized platforms that reduce time to data and enhance patient recruitment across geographies. Fourth, cultivate strategic alliances with academic institutes, biotechnology firms and contract research organizations to access cutting-edge discovery capabilities and share R&D risk. Fifth, engage payers early to align on value-based pricing models, incorporating real-world evidence and health-economic outcomes to support reimbursement negotiations. Sixth, explore combination therapy synergies by integrating PPARδ agonists with established modalities and novel biologics to address complex pathologies. Finally, prioritize patient engagement through digital health tools that improve adherence, monitor therapeutic response and foster long-term outcomes. By executing these recommendations in concert, organizations can build resilient, innovation-driven portfolios that capture the full spectrum of market opportunity.

Conclusion: Charting the Future of PPARδ Agonists

In summary, PPARδ agonists occupy a compelling position at the intersection of metabolic regulation, inflammation control and cardiovascular health. Scientific advances in ligand design and trial methodologies, coupled with evolving regulatory frameworks and digital health integration, have created an environment ripe for innovation. The recalibration of US tariff policies has underscored the need for supply chain resilience and strategic sourcing, while sophisticated segmentation models and region-specific insights are guiding targeted clinical and commercial initiatives. A constellation of leading pharmaceutical and biotechnology companies is actively advancing diverse candidates and collaboration models, further accelerating momentum. By embracing precision medicine principles, forging strategic partnerships, and proactively engaging stakeholders across the value chain, industry participants can navigate challenges and unlock sustainable growth. The convergence of scientific rigor, regulatory foresight and patient-centric approaches promises to propel PPARδ agonists from research breakthroughs to cornerstone therapies that meaningfully improve patient outcomes worldwide.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Therapeutic Application
    • Cardiovascular Disorders
      • Atherosclerosis
      • Peripheral Vascular Diseases
    • Inflammatory Disorders
      • Arthritis
      • Inflammatory Bowel Disease
    • Metabolic Disorders
      • Dyslipidemia
      • Obesity
      • Type 2 Diabetes
    • Neurological Disorders
    • Oncology
  • Pharmaceutical Formulations
    • Inhalable Formulation
    • Injectable Formulation
    • Oral Formulation
    • Topical Formulation
    • Transdermal Formulation
  • Mechanism Of Action
    • Allosteric Modulators
    • Full Agonists
    • Partial Agonists
    • Selective Agonists
  • Development Stages
    • Approved and Marketed
    • Clinical Trials
      • Phase I
      • Phase II
      • Phase III
    • Post Marketing Studies
    • Preclinical
  • Distribution Channels
    • Hospital Medication Outlets
    • Online Platforms
    • Retail Pharmacies
    • Wholesalers
  • Target Demographics
    • Age Groups
    • Gender Specific
    • Lifestyle Segments
    • Risk Profiles
      • High Risk Individuals
      • Low Risk Individuals
  • Research and Development Platforms
    • Academic Institutes
      • Applied Research
      • Basic Research
    • Biotechnology Firms
    • Contract Research Organizations
  • Combination Therapies
    • Dual Therapy
      • Synergistic Combinations
    • Monotherapy
    • Multi Therapy
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • AbbVie Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Ipsen S.A.
  • Ironwood Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Novo Nordisk A/S
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Limited
  • UCB S.A.
  • Vertex Pharmaceuticals Incorporated

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. PPARd Agonist Market, by Therapeutic Application
8.1. Introduction
8.2. Cardiovascular Disorders
8.2.1. Atherosclerosis
8.2.2. Peripheral Vascular Diseases
8.3. Inflammatory Disorders
8.3.1. Arthritis
8.3.2. Inflammatory Bowel Disease
8.4. Metabolic Disorders
8.4.1. Dyslipidemia
8.4.2. Obesity
8.4.3. Type 2 Diabetes
8.5. Neurological Disorders
8.6. Oncology
9. PPARd Agonist Market, by Pharmaceutical Formulations
9.1. Introduction
9.2. Inhalable Formulation
9.3. Injectable Formulation
9.4. Oral Formulation
9.5. Topical Formulation
9.6. Transdermal Formulation
10. PPARd Agonist Market, by Mechanism Of Action
10.1. Introduction
10.2. Allosteric Modulators
10.3. Full Agonists
10.4. Partial Agonists
10.5. Selective Agonists
11. PPARd Agonist Market, by Development Stages
11.1. Introduction
11.2. Approved And Marketed
11.3. Clinical Trials
11.3.1. Phase I
11.3.2. Phase II
11.3.3. Phase III
11.4. Post Marketing Studies
11.5. Preclinical
12. PPARd Agonist Market, by Distribution Channels
12.1. Introduction
12.2. Hospital Medication Outlets
12.3. Online Platforms
12.4. Retail Pharmacies
12.5. Wholesalers
13. PPARd Agonist Market, by Target Demographics
13.1. Introduction
13.2. Age Groups
13.3. Gender Specific
13.4. Lifestyle Segments
13.5. Risk Profiles
13.5.1. High Risk Individuals
13.5.2. Low Risk Individuals
14. PPARd Agonist Market, by Research And Development Platforms
14.1. Introduction
14.2. Academic Institutes
14.2.1. Applied Research
14.2.2. Basic Research
14.3. Biotechnology Firms
14.4. Contract Research Organizations
15. PPARd Agonist Market, by Combination Therapies
15.1. Introduction
15.2. Dual Therapy
15.2.1. Synergistic Combinations
15.3. Monotherapy
15.4. Multi Therapy
16. Americas PPARd Agonist Market
16.1. Introduction
16.2. Argentina
16.3. Brazil
16.4. Canada
16.5. Mexico
16.6. United States
17. Asia-Pacific PPARd Agonist Market
17.1. Introduction
17.2. Australia
17.3. China
17.4. India
17.5. Indonesia
17.6. Japan
17.7. Malaysia
17.8. Philippines
17.9. Singapore
17.10. South Korea
17.11. Taiwan
17.12. Thailand
17.13. Vietnam
18. Europe, Middle East & Africa PPARd Agonist Market
18.1. Introduction
18.2. Denmark
18.3. Egypt
18.4. Finland
18.5. France
18.6. Germany
18.7. Israel
18.8. Italy
18.9. Netherlands
18.10. Nigeria
18.11. Norway
18.12. Poland
18.13. Qatar
18.14. Russia
18.15. Saudi Arabia
18.16. South Africa
18.17. Spain
18.18. Sweden
18.19. Switzerland
18.20. Turkey
18.21. United Arab Emirates
18.22. United Kingdom
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. AbbVie Inc.
19.3.2. Alnylam Pharmaceuticals, Inc.
19.3.3. Amgen Inc.
19.3.4. Astellas Pharma Inc.
19.3.5. AstraZeneca PLC
19.3.6. Bayer AG
19.3.7. Biogen Inc.
19.3.8. Boehringer Ingelheim GmbH
19.3.9. Bristol-Myers Squibb Company
19.3.10. Daiichi Sankyo Company, Limited
19.3.11. Eli Lilly and Company
19.3.12. Gilead Sciences, Inc.
19.3.13. GlaxoSmithKline plc
19.3.14. Ipsen S.A.
19.3.15. Ironwood Pharmaceuticals, Inc.
19.3.16. Johnson & Johnson
19.3.17. Merck & Co., Inc.
19.3.18. Mitsubishi Tanabe Pharma Corporation
19.3.19. Novartis AG
19.3.20. Novo Nordisk A/S
19.3.21. Otsuka Holdings Co., Ltd.
19.3.22. Pfizer Inc
19.3.23. Regeneron Pharmaceuticals, Inc.
19.3.24. Roche Holding AG
19.3.25. Sanofi S.A.
19.3.26. Sumitomo Dainippon Pharma Co., Ltd.
19.3.27. Takeda Pharmaceutical Company Limited
19.3.28. Teva Pharmaceutical Industries Limited
19.3.29. UCB S.A.
19.3.30. Vertex Pharmaceuticals Incorporated
20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix
List of Figures
FIGURE 1. PPAR? AGONIST MARKET MULTI-CURRENCY
FIGURE 2. PPAR? AGONIST MARKET MULTI-LANGUAGE
FIGURE 3. PPAR? AGONIST MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL PPAR? AGONIST MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL PPAR? AGONIST MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL PPAR? AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PPAR? AGONIST MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PPAR? AGONIST MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PPAR? AGONIST MARKET SIZE, BY PHARMACEUTICAL FORMULATIONS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PPAR? AGONIST MARKET SIZE, BY PHARMACEUTICAL FORMULATIONS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PPAR? AGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PPAR? AGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PPAR? AGONIST MARKET SIZE, BY DEVELOPMENT STAGES, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PPAR? AGONIST MARKET SIZE, BY DEVELOPMENT STAGES, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL PPAR? AGONIST MARKET SIZE, BY DISTRIBUTION CHANNELS, 2024 VS 2030 (%)
FIGURE 16. GLOBAL PPAR? AGONIST MARKET SIZE, BY DISTRIBUTION CHANNELS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL PPAR? AGONIST MARKET SIZE, BY TARGET DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 18. GLOBAL PPAR? AGONIST MARKET SIZE, BY TARGET DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL PPAR? AGONIST MARKET SIZE, BY RESEARCH AND DEVELOPMENT PLATFORMS, 2024 VS 2030 (%)
FIGURE 20. GLOBAL PPAR? AGONIST MARKET SIZE, BY RESEARCH AND DEVELOPMENT PLATFORMS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL PPAR? AGONIST MARKET SIZE, BY COMBINATION THERAPIES, 2024 VS 2030 (%)
FIGURE 22. GLOBAL PPAR? AGONIST MARKET SIZE, BY COMBINATION THERAPIES, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AMERICAS PPAR? AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. AMERICAS PPAR? AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. UNITED STATES PPAR? AGONIST MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 26. UNITED STATES PPAR? AGONIST MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC PPAR? AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC PPAR? AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. EUROPE, MIDDLE EAST & AFRICA PPAR? AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. EUROPE, MIDDLE EAST & AFRICA PPAR? AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. PPAR? AGONIST MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 32. PPAR? AGONIST MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. PPAR? AGONIST MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PPAR? AGONIST MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PPAR? AGONIST MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PPAR? AGONIST MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL PPAR? AGONIST MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL PPAR? AGONIST MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PPAR? AGONIST MARKET SIZE, BY ATHEROSCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PPAR? AGONIST MARKET SIZE, BY PERIPHERAL VASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PPAR? AGONIST MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PPAR? AGONIST MARKET SIZE, BY INFLAMMATORY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PPAR? AGONIST MARKET SIZE, BY ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PPAR? AGONIST MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PPAR? AGONIST MARKET SIZE, BY INFLAMMATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PPAR? AGONIST MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PPAR? AGONIST MARKET SIZE, BY DYSLIPIDEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PPAR? AGONIST MARKET SIZE, BY OBESITY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PPAR? AGONIST MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PPAR? AGONIST MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PPAR? AGONIST MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PPAR? AGONIST MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL PPAR? AGONIST MARKET SIZE, BY PHARMACEUTICAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL PPAR? AGONIST MARKET SIZE, BY INHALABLE FORMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL PPAR? AGONIST MARKET SIZE, BY INJECTABLE FORMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL PPAR? AGONIST MARKET SIZE, BY ORAL FORMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL PPAR? AGONIST MARKET SIZE, BY TOPICAL FORMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL PPAR? AGONIST MARKET SIZE, BY TRANSDERMAL FORMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL PPAR? AGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL PPAR? AGONIST MARKET SIZE, BY ALLOSTERIC MODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL PPAR? AGONIST MARKET SIZE, BY FULL AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL PPAR? AGONIST MARKET SIZE, BY PARTIAL AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL PPAR? AGONIST MARKET SIZE, BY SELECTIVE AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL PPAR? AGONIST MARKET SIZE, BY DEVELOPMENT STAGES, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL PPAR? AGONIST MARKET SIZE, BY APPROVED AND MARKETED, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL PPAR? AGONIST MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL PPAR? AGONIST MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL PPAR? AGONIST MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL PPAR? AGONIST MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL PPAR? AGONIST MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL PPAR? AGONIST MARKET SIZE, BY POST MARKETING STUDIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL PPAR? AGONIST MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL PPAR? AGONIST MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL PPAR? AGONIST MARKET SIZE, BY HOSPITAL MEDICATION OUTLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL PPAR? AGONIST MARKET SIZE, BY ONLINE PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL PPAR? AGONIST MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL PPAR? AGONIST MARKET SIZE, BY WHOLESALERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL PPAR? AGONIST MARKET SIZE, BY TARGET DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL PPAR? AGONIST MARKET SIZE, BY AGE GROUPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL PPAR? AGONIST MARKET SIZE, BY GENDER SPECIFIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL PPAR? AGONIST MARKET SIZE, BY LIFESTYLE SEGMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL PPAR? AGONIST MARKET SIZE, BY RISK PROFILES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL PPAR? AGONIST MARKET SIZE, BY HIGH RISK INDIVIDUALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL PPAR? AGONIST MARKET SIZE, BY LOW RISK INDIVIDUALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL PPAR? AGONIST MARKET SIZE, BY RISK PROFILES, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL PPAR? AGONIST MARKET SIZE, BY RESEARCH AND DEVELOPMENT PLATFORMS, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL PPAR? AGONIST MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL PPAR? AGONIST MARKET SIZE, BY APPLIED RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL PPAR? AGONIST MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL PPAR? AGONIST MARKET SIZE, BY ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL PPAR? AGONIST MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL PPAR? AGONIST MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL PPAR? AGONIST MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL PPAR? AGONIST MARKET SIZE, BY DUAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL PPAR? AGONIST MARKET SIZE, BY SYNERGISTIC COMBINATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL PPAR? AGONIST MARKET SIZE, BY DUAL THERAPY, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL PPAR? AGONIST MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL PPAR? AGONIST MARKET SIZE, BY MULTI THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS PPAR? AGONIST MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS PPAR? AGONIST MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS PPAR? AGONIST MARKET SIZE, BY INFLAMMATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS PPAR? AGONIST MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS PPAR? AGONIST MARKET SIZE, BY PHARMACEUTICAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS PPAR? AGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS PPAR? AGONIST MARKET SIZE, BY DEVELOPMENT STAGES, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS PPAR? AGONIST MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS PPAR? AGONIST MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS PPAR? AGONIST MARKET SIZE, BY TARGET DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS PPAR? AGONIST MARKET SIZE, BY RISK PROFILES, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS PPAR? AGONIST MARKET SIZE, BY RESEARCH AND DEVELOPMENT PLATFORMS, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS PPAR? AGONIST MARKET SIZE, BY ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS PPAR? AGONIST MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS PPAR? AGONIST MARKET SIZE, BY DUAL THERAPY, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS PPAR? AGONIST MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA PPAR? AGONIST MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA PPAR? AGONIST MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA PPAR? AGONIST MARKET SIZE, BY INFLAMMATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA PPAR? AGONIST MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA PPAR? AGONIST MARKET SIZE, BY PHARMACEUTICAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA PPAR? AGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA PPAR? AGONIST MARKET SIZE, BY DEVELOPMENT STAGES, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA PPAR? AGONIST MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA PPAR? AGONIST MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA PPAR? AGONIST MARKET SIZE, BY TARGET DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA PPAR? AGONIST MARKET SIZE, BY RISK PROFILES, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA PPAR? AGONIST MARKET SIZE, BY RESEARCH AND DEVELOPMENT PLATFORMS, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA PPAR? AGONIST MARKET SIZE, BY ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA PPAR? AGONIST MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA PPAR? AGONIST MARKET SIZE, BY DUAL THERAPY, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL PPAR? AGONIST MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL PPAR? AGONIST MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL PPAR? AGONIST MARKET SIZE, BY INFLAMMATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL PPAR? AGONIST MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL PPAR? AGONIST MARKET SIZE, BY PHARMACEUTICAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL PPAR? AGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL PPAR? AGONIST MARKET SIZE, BY DEVELOPMENT STAGES, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL PPAR? AGONIST MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL PPAR? AGONIST MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL PPAR? AGONIST MARKET SIZE, BY TARGET DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL PPAR? AGONIST MARKET SIZE, BY RISK PROFILES, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL PPAR? AGONIST MARKET SIZE, BY RESEARCH AND DEVELOPMENT PLATFORMS, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL PPAR? AGONIST MARKET SIZE, BY ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL PPAR? AGONIST MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL PPAR? AGONIST MARKET SIZE, BY DUAL THERAPY, 2018-2030 (USD MILLION)
TABLE 114. CANADA PPAR? AGONIST MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 115. CANADA PPAR? AGONIST MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
TABLE 116. CANADA PPAR? AGONIST MARKET SIZE, BY INFLAMMATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 117. CANADA PPAR? AGONIST MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 118. CANADA PPAR? AGONIST MARKET SIZE, BY PHARMACEUTICAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 119. CANADA PPAR? AGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 120. CANADA PPAR? AGONIST MARKET SIZE, BY DEVELOPMENT STAGES, 2018-2030 (USD MILLION)
TABLE 121. CANADA PPAR? AGONIST MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 122. CANADA PPAR? AGONIST MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 123. CANADA PPAR? AGONIST MARKET SIZE, BY TARGET DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 124. CANADA PPAR? AGONIST MARKET SIZE, BY RISK PROFILES, 2018-2030 (USD MILLION)
TABLE 125. CANADA PPAR? AGONIST MARKET SIZE, BY RESEARCH AND DEVELOPMENT PLATFORMS, 2018-2030 (USD MILLION)
TABLE 126. CANADA PPAR? AGONIST MARKET SIZE, BY ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 127. CANADA PPAR? AGONIST MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 128. CANADA PPAR? AGONIST MARKET SIZE, BY DUAL THERAPY, 2018-2030 (USD MILLION)
TABLE 129. MEXICO PPAR? AGONIST MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 130. MEXICO PPAR? AGONIST MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
TABLE 131. MEXICO PPAR? AGONIST MARKET SIZE, BY INFLAMMATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 132. MEXICO PPAR? AGONIST MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 133. MEXICO PPAR? AGONIST MARKET SIZE, BY PHARMACEUTICAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 134. MEXICO PPAR? AGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 135. MEXICO PPAR? AGONIST MARKET SIZE, BY DEVELOPMENT STAGES, 2018-2030 (USD MILLION)
TABLE 136. MEXICO PPAR? AGONIST MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 137. MEXICO PPAR? AGONIST MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 138. MEXICO PPAR? AGONIST MARKET SIZE, BY TARGET DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 139. MEXICO PPAR? AGONIST MARKET SIZE, BY RISK PROFILES, 2018-2030 (USD MILLION)
TABLE 140. MEXICO PPAR? AGONIST MARKET SIZE, BY RESEARCH AND DEVELOPMENT PLATFORMS, 2018-2030 (USD MILLION)
TABLE 141. MEXICO PPAR? AGONIST MARKET SIZE, BY ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 142. MEXICO PPAR? AGONIST MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 143. MEXICO PPAR? AGONIST MARKET SIZE, BY DUAL THERAPY, 2018-2030 (USD MILLION)
TABLE 144. UNITED STATES PPAR? AGONIST MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 145. UNITED STATES PPAR? AGONIST MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
TABLE 146. UNITED STATES PPAR? AGONIST MARKET SIZE, BY INFLAMMATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 147. UNITED STATES PPAR? AGONIST MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 148. UNITED STATES PPAR? AGONIST MARKET SIZE, BY PHARMACEUTICAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 149. UNITED STATES PPAR? AGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 150. UNITED STATES PPAR? AGONIST MARKET SIZE, BY DEVELOPMENT STAGES, 2018-2030 (USD MILLION)
TABLE 151. UNITED STATES PPAR? AGONIST MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 152. UNITED STATES PPAR? AGONIST MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 153. UNITED STATES PPAR? AGONIST MARKET SIZE, BY TARGET DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 154. UNITED STATES PPAR? AGONIST MARKET SIZE, BY RISK PROFILES, 2018-2030 (USD MILLION)
TABLE 155. UNITED STATES PPAR? AGONIST MARKET SIZE, BY RESEARCH AND DEVELOPMENT PLATFORMS, 2018-2030 (USD MILLION)
TABLE 156. UNITED STATES PPAR? AGONIST MARKET SIZE, BY ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 157. UNITED STATES PPAR? AGONIST MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 158. UNITED STATES PPAR? AGONIST MARKET SIZE, BY DUAL THERAPY, 2018-2030 (USD MILLION)
TABLE 159. UNITED STATES PPAR? AGONIST MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 160. ASIA-PACIFIC PPAR? AGONIST MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 161. ASIA-PACIFIC PPAR? AGONIST MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
TABLE 162. ASIA-PACIFIC PPAR? AGONIST MARKET SIZE, BY INFLAMMATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 163. ASIA-PACIFIC PPAR? AGONIST MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 164. ASIA-PACIFIC PPAR? AGONIST MARKET SIZE, BY PHARMACEUTICAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 165. ASIA-PACIFIC PPAR? AGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 166. ASIA-PACIFIC PPAR? AGONIST MARKET SIZE, BY DEVELOPMENT STAGES, 2018-2030 (USD MILLION)
TABLE 167. ASIA-PACIFIC PPAR? AGONIST MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 168. ASIA-PACIFIC PPAR? AGONIST MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 169. ASIA-PACIFIC PPAR? AGONIST MARKET SIZE, BY TARGET DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 170. ASIA-PACIFIC PPAR? AGONIST MARKET SIZE, BY RISK PROFILES, 2018-2030 (USD MILLION)
TABLE 171. ASIA-PACIFIC PPAR? AGONIST MARKET SIZE, BY RESEARCH AND DEVELOPMENT PLATFORMS, 2018-2030 (USD MILLION)
TABLE 172. ASIA-PACIFIC PPAR? AGONIST MARKET SIZE, BY ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 173. ASIA-PACIFIC PPAR? AGONIST MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 174. ASIA-PACIFIC PPAR? AGONIST MARKET SIZE, BY DUAL THERAPY, 2018-2030 (USD MILLION)
TABLE 175. ASIA-PACIFIC PPAR? AGONIST MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 176. AUSTRALIA PPAR? AGONIST MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 177. AUSTRALIA PPAR? AGONIST MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
TABLE 178. AUSTRALIA PPAR? AGONIST MARKET SIZE, BY INFLAMMATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 179. AUSTRALIA PPAR? AGONIST MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 180. AUSTRALIA PPAR? AGONIST MARKET SIZE, BY PHARMACEUTICAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 181. AUSTRALIA PPAR? AGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 182. AUSTRALIA PPAR? AGONIST MARKET SIZE, BY DEVELOPMENT STAGES, 2018-2030 (USD MILLION)
TABLE 183. AUSTRALIA PPAR? AGONIST MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 184. AUSTRALIA PPAR? AGONIST MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 185. AUSTRALIA PPAR? AGONIST MARKET SIZE, BY TARGET DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 186. AUSTRALIA PPAR? AGONIST MARKET SIZE, BY RISK PROFILES, 2018-2030 (USD MILLION)
TABLE 187. AUSTRALIA PPAR? AGONIST MARKET SIZE, BY RESEARCH AND DEVELOPMENT PLATFORMS, 2018-2030 (USD MILLION)
TABLE 188. AUSTRALIA PPAR? AGONIST MARKET SIZE, BY ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 189. AUSTRALIA PPAR? AGONIST MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 190. AUSTRALIA PPAR? AGONIST MARKET SIZE, BY DUAL THERAPY, 2018-2030 (USD MILLION)
TABLE 191. CHINA PPAR? AGONIST MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 192. CHINA PPAR? AGONIST MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
TABLE 193. CHINA PPAR? AGONIST MARKET SIZE, BY INFLAMMATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 194. CHINA PPAR? AGONIST MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 195. CHINA PPAR? AGONIST MARKET SIZE, BY PHARMACEUTICAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 196. CHINA PPAR? AGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 197. CHINA PPAR? AGONIST MARKET SIZE, BY DEVELOPMENT STAGES, 2018-2030 (USD MILLION)
TABLE 198. CHINA PPAR? AGONIST MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 199. CHINA PPAR? AGONIST MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 200. CHINA PPAR? AGONIST MARKET SIZE, BY TARGET DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 201. CHINA PPAR? AGONIST MARKET SIZE, BY RISK PROFILES, 2018-2030 (USD MILLION)
TABLE 202. CHINA PPAR? AGONIST MARKET SIZE, BY RESEARCH AND DEVELOPMENT PLATFORMS, 2018-2030 (USD MILLION)
TABLE 203. CHINA PPAR? AGONIST MARKET SIZE, BY ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 204. CHINA PPAR? AGONIST MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 205. CHINA PPAR? AGONIST MARKET SIZE, BY DUAL THERAPY, 2018-2030 (USD MILLION)
TABLE 206. INDIA PPAR? AGONIST MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 207. INDIA PPAR? AGONIST MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
TABLE 208. INDIA PPAR? AGONIST MARKET SIZE, BY INFLAMMATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 209. INDIA PPAR? AGONIST MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 210. INDIA PPAR? AGONIST MARKET SIZE, BY PHARMACEUTICAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 211. INDIA PPAR? AGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 212. INDIA PPAR? AGONIST MARKET SIZE, BY DEVELOPMENT STAGES, 2018-2030 (USD MILLION)
TABLE 213. INDIA PPAR? AGONIST MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 214. INDIA PPAR? AGONIST MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 215. INDIA PPAR? AGONIST MARKET SIZE, BY TARGET DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 216. INDIA PPAR? AGONIST MARKET SIZE, BY RISK PROFILES, 2018-2030 (USD MILLION)
TABLE 217. INDIA PPAR? AGONIST MARKET SIZE, BY RESEARCH AND DEVELOPMENT PLATFORMS, 2018-2030 (USD MILLION)
TABLE 218. INDIA PPAR? AGONIST MARKET SIZE, BY ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 219. INDIA PPAR? AGONIST MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 220. INDIA PPAR? AGONIST MARKET SIZE, BY DUAL THERAPY, 2018-2030 (USD MILLION)
TABLE 221. INDONESIA PPAR? AGONIST MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 222. INDONESIA PPAR? AGONIST MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
TABLE 223. INDONESIA PPAR? AGONIST MARKET SIZE, BY INFLAMMATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 224. INDONESIA PPAR? AGONIST MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 225. INDONESIA PPAR? AGONIST MARKET SIZE, BY PHARMACEUTICAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 226. INDONESIA PPAR? AGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 227. INDONESIA PPAR? AGONIST MARKET SIZE, BY DEVELOPMENT STAGES, 2018-2030 (USD MILLION)
TABLE 228. INDONESIA PPAR? AGONIST MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 229. INDONESIA PPAR? AGONIST MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 230. INDONESIA PPAR? AGONIST MARKET SIZE, BY TARGET DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 231. INDONESIA PPAR? AGONIST MARKET SIZE, BY RISK PROFILES, 2018-2030 (USD MILLION)
TABLE 232. INDONESIA PPAR? AGONIST MARKET SIZE, BY RESEARCH AND DEVELOPMENT PLATFORMS, 2018-2030 (USD MILLION)
TABLE 233. INDONESIA PPAR? AGONIST MARKET SIZE, BY ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 234. INDONESIA PPAR? AGONIST MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 235. INDONESIA PPAR? AGONIST MARKET SIZE, BY DUAL THERAPY, 2018-2030 (USD MILLION)
TABLE 236. JAPAN PPAR? AGONIST MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 237. JAPAN PPAR? AGONIST MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
TABLE 238. JAPAN PPAR? AGONIST MARKET SIZE, BY INFLAMMATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 239. JAPAN PPAR? AGONIST MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 240. JAPAN PPAR? AGONIST MARKET SIZE, BY PHARMACEUTICAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 241. JAPAN PPAR? AGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 242. JAPAN PPAR? AGONIST MARKET SIZE, BY DEVELOPMENT STAGES, 2018-2030 (USD MILLION)
TABLE 243. JAPAN PPAR? AGONIST MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 244. JAPAN PPAR? AGONIST MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 245. JAPAN PPAR? AGONIST MARKET SIZE, BY TARGET DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 246. JAPAN PPAR? AGONIST MARKET SIZE, BY RISK PROFILES, 2018-2030 (USD MILLION)
TABLE 247. JAPAN PPAR? AGONIST MARKET SIZE, BY RESEARCH AND DEVELOPMENT PLATFORMS, 2018-2030 (USD MILLION)
TABLE 248. JAPAN PPAR? AGONIST MARKET SIZE, BY ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 249. JAPAN PPAR? AGONIST MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 250. JAPAN PPAR? AGONIST MARKET SIZE, BY DUAL THERAPY, 2018-2030 (USD MILLION)
TABLE 251. MALAYSIA PPAR? AGONIST MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 252. MALAYSIA PPAR? AGONIST MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
TABLE 253. MALAYSIA PPAR? AGONIST MARKET SIZE, BY INFLAMMATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 254. MALAYSIA PPAR? AGONIST MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 255. MALAYSIA PPAR? AGONIST MARKET SIZE, BY PHARMACEUTICAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 256. MALAYSIA PPAR? AGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 257. MALAYSIA PPAR? AGONIST MARKET SIZE, BY DEVELOPMENT STAGES, 2018-2030 (USD MILLION)
TABLE 258. MALAYSIA PPAR? AGONIST MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 259. MALAYSIA PPAR? AGONIST MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 260. MALAYSIA PPAR? AGONIST MARKET SIZE, BY TARGET DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 261. MALAYSIA PPAR? AGONIST MARKET SIZE, BY RISK PROFILES, 2018-2030 (USD MILLION)
TABLE 262. MALAYSIA PPAR? AGONIST MARKET SIZE, BY RESEARCH AND DEVELOPMENT PLATFORMS, 2018-2030 (USD MILLION)
TABLE 263. MALAYSIA PPAR? AGONIST MARKET SIZE, BY ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 264. MALAYSIA PPAR? AGONIST MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 265. MALAYSIA PPAR? AGONIST MARKET SIZE, BY DUAL THERAPY, 2018-2030 (USD MILLION)
TABLE 266. PHILIPPINES PPAR? AGONIST MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 267. PHILIPPINES PPAR? AGONIST MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
TABLE 268. PHILIPPINES PPAR? AGONIST MARKET SIZE, BY INFLAMMATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 269. PHILIPPINES PPAR? AGONIST MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 270. PHILIPPINES PPAR? AGONIST MARKET SIZE, BY PHARMACEUTICAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 271. PHILIPPINES PPAR? AGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 272. PHILIPPINES PPAR? AGONIST MARKET SIZE, BY DEVELOPMENT STAGES, 2018-2030 (USD MILLION)
TABLE 273. PHILIPPINES PPAR? AGONIST MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 274. PHILIPPINES PPAR? AGONIST MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 275. PHILIPPINES PPAR? AGONIST MARKET SIZE, BY TARGET DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 276. PHILIPPINES PPAR? AGONIST MARKET SIZE, BY RISK PROFILES, 2018-2030 (USD MILLION)
TABLE 277. PHILIPPINES PPAR? AGONIST MARKET SIZE, BY RESEARCH AND DEVELOPMENT PLATFORMS, 2018-2030 (USD MILLION)
TABLE 278. PHILIPPINES PPAR? AGONIST MARKET SIZE, BY ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 279. PHILIPPINES PPAR? AGONIST MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 280. PHILIPPINES PPAR? AGONIST MARKET SIZE, BY DUAL THERAPY, 2018-2030 (USD MILLION)
TABLE 281. SINGAPORE PPAR? AGONIST MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 282. SINGAPORE PPAR? AGONIST MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
TABLE 283. SINGAPORE PPAR? AGONIST MARKET SIZE, BY INFLAMMATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 284. SINGAPORE PPAR? AGONIST MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 285. SINGAPORE PPAR? AGONIST MARKET SIZE, BY PHARMACEUTICAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 286. SINGAPORE PPAR? AGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 287. SINGAPORE PPAR? AGONIST MARKET SIZE, BY DEVELOPMENT STAGES, 2018-2030 (USD MILLION)
TABLE 288. SINGAPORE PPAR? AGONIST MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 289. SINGAPORE PPAR? AGONIST MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 290. SINGAPORE PPAR? AGONIST MARKET SIZE, BY TARGET DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 291. SINGAPORE PPAR? AGONIST MARKET SIZE, BY RISK PROFILES, 2018-2030 (USD MILLION)
TABLE 292. SINGAPORE PPAR? AGONIST MARKET SIZE, BY RESEARCH AND DEVELOPMENT PLATFORMS, 2018-2030 (USD MILLION)
TABLE 293. SINGAPORE PPAR? AGONIST MARKET SIZE, BY ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 294. SINGAPORE PPAR? AGONIST MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 295. SINGAPORE PPAR? AGONIST MARKET SIZE, BY DUAL THERAPY, 2018-2030 (USD MILLION)
TABLE 296. SOUTH KOREA PPAR? AGONIST MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 297. SOUTH KOREA PPAR? AGONIST MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
TABLE 298. SOUTH KOREA PPAR? AGONIST MARKET SIZE, BY INFLAMMATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 299. SOUTH KOREA PPAR? AGONIST MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 300. SOUTH KOREA PPAR? AGONIST MARKET SIZE, BY PHARMACEUTICAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 301. SOUTH KOREA PPAR? AGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 302. SOUTH KOREA PPAR? AGONIST MARKET SIZE, BY DEVELOPMENT STAGES, 2018-2030 (USD MILLION)
TABLE 303. SOUTH KOREA PPAR? AGONIST MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 304. SOUTH KOREA PPAR? AGONIST MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 305. SOUTH KOREA PPAR? AGONIST MARKET SIZE, BY TARGET DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 306. SOUTH KOREA PPAR? AGONIST MARKET SIZE, BY RISK PROFILES, 2018-2030 (USD MILLION)
TABLE 307. SOUTH KOREA PPAR? AGONIST MARKET SIZE, BY RESEARCH AND DEVELOPMENT PLATFORMS, 2018-2030 (USD MILLION)
TABLE 308. SOUTH KOREA PPAR? AGONIST MARKET SIZE, BY ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 309. SOUTH KOREA PPAR? AGONIST MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 310. SOUTH KOREA PPAR? AGONIST MARKET SIZE, BY DUAL THERAPY, 2018-2030 (USD MILLION)
TABLE 311. TAIWAN PPAR? AGONIST MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 312. TAIWAN PPAR? AGONIST MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
TABLE 313. TAIWAN PPAR? AGONIST MARKET SIZE, BY INFLAMMATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 314. TAIWAN PPAR? AGONIST MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 315. TAIWAN PPAR? AGONIST MARKET SIZE, BY PHARMACEUTICAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 316. TAIWAN PPAR? AGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 317. TAIWAN PPAR? AGONIST MARKET SIZE, BY DEVELOPMENT STAGES, 2018-2030 (USD MILLION)
TABLE 318. TAIWAN PPAR? AGONIST MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 319. TAIWAN PPAR? AGONIST MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 320. TAIWAN PPAR? AGONIST MARKET SIZE, BY TARGET DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 321. TAIWAN PPAR? AGONIST MARKET SIZE, BY RISK PROFILES, 2018-2030 (USD MILLION)
TABLE 322. TAIWAN PPAR? AGONIST MARKET SIZE, BY RESEARCH AND DEVELOPMENT PLATFORMS, 2018-2030 (USD MILLION)
TABLE 323. TAIWAN PPAR? AGONIST MARKET SIZE, BY ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 324. TAIWAN PPAR? AGONIST MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 325. TAIWAN PPAR? AGONIST MARKET SIZE, BY DUAL THERAPY, 2018-2030 (USD MILLION)
TABLE 326. THAILAND PPAR? AGONIST MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 327. THAILAND PPAR? AGONIST MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
TABLE 328. THAILAND PPAR? AGONIST MARKET SIZE, BY INFLAMMATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 329. THAILAND PPAR? AGONIST MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 330. THAILAND PPAR? AGONIST MARKET SIZE, BY PHARMACEUTICAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 331. THAILAND PPAR? AGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 332. THAILAND PPAR? AGONIST MARKET SIZE, BY DEVELOPMENT STAGES, 2018-2030 (USD MILLION)
TABLE 333. THAILAND PPAR? AGONIST MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 334. THAILAND PPAR? AGONIST MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 335. THAILAND PPAR? AGONIST MARKET SIZE, BY TARGET DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 336. THAILAND PPAR? AGONIST MARKET SIZE, BY RISK PROFILES, 2018-2030 (USD MILLION)
TABLE 337. THAILAND PPAR? AGONIST MARKET SIZE, BY RESEARCH AND DEVELOPMENT PLATFORMS, 2018-2030 (USD MILLION)
TABLE 338. THAILAND PPAR? AGONIST MARKET SIZE, BY ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 339. THAILAND PPAR? AGONIST MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 340. THAILAND PPAR? AGONIST MARKET SIZE, BY DUAL THERAPY, 2018-2030 (USD MILLION)
TABLE 341

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this PPARδ Agonist market report include:
  • AbbVie Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Ipsen S.A.
  • Ironwood Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Novo Nordisk A/S
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Limited
  • UCB S.A.
  • Vertex Pharmaceuticals Incorporated

Related Topics

Related Reports

MIN-102 Emerging Drug Insight and Market Forecast - 2032 - Product Image

MIN-102 Emerging Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • 30 Pages
  • Global
From
Drug Discovery Stories. From Bench to Bedside - Product Image

Drug Discovery Stories. From Bench to Bedside

  • Book
GLP-1R Agonists - Label Extensions/Drug Repurposing: Market Overview - Product Image

GLP-1R Agonists - Label Extensions/Drug Repurposing: Market Overview

  • Report
  • 73 Pages
  • Global
From
Tirzepatide, Emerging Drug Insight and Market Forecast - 2032 - Product Image

Tirzepatide, Emerging Drug Insight and Market Forecast - 2032

  • Report
  • 30 Pages
  • Global
From
Brody's Human Pharmacology. Edition No. 7 - Product Image

Brody's Human Pharmacology. Edition No. 7

  • Book
Copyright © 2002-2025 Research and Markets. All Rights Reserved.